UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake

Obesity (Silver Spring, Md.), 2016-11, Vol.24 (11), p.2289-2295

2016

Volltextzugriff (PDF)

Hepatic and Extrahepatic Insulin Clearance Are Differentially Regulated: Results From a Novel Model-Based Analysis of Intravenous Glucose Tolerance Data

Diabetes (New York, N.Y.), 2016-06, Vol.65 (6), p.1556-1564

2016

Volltextzugriff (PDF)

Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content

The journal of clinical endocrinology and metabolism, 2019-05, Vol.104 (5), p.1855-1865

2019

Volltextzugriff (PDF)

Hepatic but Not Extrahepatic Insulin Clearance Is Lower in African American Than in European American Women

Diabetes (New York, N.Y.), 2017-10, Vol.66 (10), p.2564-2570

2017

Volltextzugriff (PDF)

Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on insulin kinetics

The Journal of clinical investigation, 2020-06, Vol.130 (6), p.3305-3314

2020

Volltextzugriff (PDF)

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

PloS one, 2012-02, Vol.7 (2), p.e30555-e30555

2012

Volltextzugriff (PDF)

Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy Participants

Clinical therapeutics, 2014-05, Vol.36 (5), p.698-710

2014

Volltextzugriff (PDF)

Response to Letter to the Editor: “Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content”

The journal of clinical endocrinology and metabolism, 2019-11, Vol.104 (11), p.5251-5252

2019

Volltextzugriff (PDF)

Dissection of hepatic versus extra‐hepatic insulin clearance: Ethnic differences in childhood

Diabetes, obesity & metabolism, 2018-12, Vol.20 (12), p.2869-2875

2018

Volltextzugriff (PDF)

Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus

Annals of the New York Academy of Sciences, 2015-11, Vol.1358 (1), p.28-43

2015

Volltextzugriff (PDF)

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

PloS one, 2014-08, Vol.9 (8), p.e105638

2014

Volltextzugriff (PDF)

Clinical Pharmacokinetic, Pharmacodynamic, and Drug–Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor

Clinical pharmacokinetics, 2015-10, Vol.54 (10), p.1027-1041

2015

Volltextzugriff (PDF)

JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans

Scientific reports, 2024-07, Vol.14 (1), p.17515-12, Article 17515

2024

Volltextzugriff (PDF)

GNSS Radio Frequency Interference Monitoring from LEO Satellites: An In-Laboratory Prototype

Sensors (Basel, Switzerland), 2024-01, Vol.24 (2), p.508

2024

Volltextzugriff (PDF)

A long‐acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese nonhuman primate model

Clinical and translational science, 2023-08, Vol.16 (8), p.1431-1444

2023

Volltextzugriff (PDF)

Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport

Diabetes care, 2015-12, Vol.38 (12), p.2344-2353

2015

Volltextzugriff (PDF)

Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants

Clinical therapeutics, 2016-01, Vol.38 (1), p.89-98.e1

2016

Volltextzugriff (PDF)

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

PloS one, 2014, Vol.9 (9), p.e110069

2014

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects

Clinical therapeutics, 2015-07, Vol.37 (7), p.1483-1492.e1

2015

Volltextzugriff (PDF)

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes

Diabetologia, 2014-05, Vol.57 (5), p.891-901

2014

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants

International journal of clinical pharmacology and therapeutics, 2015-06, Vol.53 (6), p.438-446

2015

Volltextzugriff (PDF)

Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes

Diabetes care, 2015-12, Vol.38 (12), p.2258-2265

2015

Volltextzugriff (PDF)

Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside

Diabetes care, 2015-12, Vol.38 (12), p.2344-2353

2015

Volltextzugriff (PDF)

Alteration of the Glucagon Axis in GPR120 (FFAR4) Knockout Mice

The Journal of biological chemistry, 2014-05, Vol.289 (22), p.15751-15763

2014

Volltextzugriff (PDF)

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

Diabetes care, 2012-06, Vol.35 (6), p.1232-1238

2012

Volltextzugriff (PDF)

1 – 25 von 134

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(119)
Mit Volltextzugriff
(118)

Publikationsform

Sprache

Englisch
(134)

Erscheinungsjahr

n.n

Thema

Science & Technology
(92)
Life Sciences & Biomedicine
(79)
Humans
(55)
Male
(43)
Female
(39)
Adult
(29)
Middle Aged
(29)
Endocrinology & Metabolism
(27)
Diabetes
(26)
Glucose
(23)
Canagliflozin
(20)
Insulin
(19)
Animals
(18)
Diabetes Mellitus, Type 2 - Drug Therapy
(16)
Sodium-Glucose Transporter 2 - Antagonists & Inhibitors
(16)
Biological And Medical Sciences
(14)
Blood Glucose - Metabolism
(14)
Type 2 Diabetes
(14)
Young Adult
(14)
Aged
(13)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake

Hepatic and Extrahepatic Insulin Clearance Are Differentially Regulated: Results From a Novel Model-Based Analysis of Intravenous Glucose Tolerance Data

Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content

Hepatic but Not Extrahepatic Insulin Clearance Is Lower in African American Than in European American Women

Influence of adiposity, insulin resistance, and intrahepatic triglyceride content on insulin kinetics

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

Effects of Hydrochlorothiazide on the Pharmacokinetics, Pharmacodynamics, and Tolerability of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Healthy Participants

Response to Letter to the Editor: “Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content”

Dissection of hepatic versus extra‐hepatic insulin clearance: Ethnic differences in childhood

Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

Clinical Pharmacokinetic, Pharmacodynamic, and Drug–Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor

JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans

GNSS Radio Frequency Interference Monitoring from LEO Satellites: An In-Laboratory Prototype

A long‐acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese nonhuman primate model

Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport

Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants

Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes

Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes

Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants

Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes

Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside

Alteration of the Glucagon Axis in GPR120 (FFAR4) Knockout Mice

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

Suchergebnisse filtern